NRAS and melanoma: This finding reinforces the idea that NRAS mutational analysis should be included in routine diagnosis as a predictive biomarker of response to therapy, to select the group of patients that would benefit more from the administration of immunotherapies, even though specific therapeutic options do not exist for NRAS-mutant melanoma patients.